English
Interleukine-2 (IL-2) is a cytokine with both immune stimulating and suppressive function. Consequently, it has been used in the clinic at high doses to stimulate the immune response against cancer and more recently at low doses to block the immune response in type 1 diabetes (T1D) and graft versus host disease (GVHD). When IL-2 is complexed with an anti- IL-2 antibody (Ab), IL-2 pharmacodynamics is improved, its toxicity is lowered and depending on the Ab, this complex can direct IL-2 action to effector or to regulatory immune cells, solving the main problems associated with IL-2-based therapies. In this collaborative project with an international company , we propose to generate anti-IL-2 Abs from a new identified, screen them for their capacity to stimulate or inhibit the immune response and finally test their therapeutic capacity in mouse models of T1D or cancer, in view of clinical application.
